Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-2-18
pubmed:abstractText
Human glutamate carboxypeptidase II (GCPII) is involved in neuronal signal transduction and intestinal folate absorption by means of the hydrolysis of its two natural substrates, N-acetyl-aspartyl-glutamate and folyl-poly-gamma-glutamates, respectively. During the past years, tremendous efforts have been made toward the structural analysis of GCPII. Crystal structures of GCPII in complex with various ligands have provided insight into the binding of these ligands, particularly to the S1' site of the enzyme. In this article, we have extended structural characterization of GCPII to its S1 site by using dipeptide-based inhibitors that interact with both S1 and S1' sites of the enzyme. To this end, we have determined crystal structures of human GCPII in complex with phosphapeptide analogs of folyl-gamma-glutamate, aspartyl-glutamate, and gamma-glutamyl-glutamate, refined at 1.50, 1.60, and 1.67 A resolution, respectively. The S1 pocket of GCPII could be accurately defined and analyzed for the first time, and the data indicate the importance of Asn519, Arg463, Arg534, and Arg536 for recognition of the penultimate (i.e., P1) substrate residues. Direct interactions between the positively charged guanidinium groups of Arg534 and Arg536 and a P1 moiety of a substrate/inhibitor provide mechanistic explanation of GCPII preference for acidic dipeptides. Additionally, observed conformational flexibility of the Arg463 and Arg536 side chains likely regulates GCPII affinity toward different inhibitors and modulates GCPII substrate specificity. The biochemical experiments assessing the hydrolysis of several GCPII substrate derivatives modified at the P1 position, also included in this report, further complement and extend conclusions derived from the structural analysis. The data described here form an a solid foundation for the structurally aided design of novel low-molecular-weight GCPII inhibitors and imaging agents.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-10085079, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-10089341, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-10089417, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-10222271, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-10581082, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-10668445, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-10715144, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-11462970, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-11463268, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-11708918, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-11905994, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-12127534, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-12714052, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-12849974, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-15027864, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-15044850, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-15801825, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-15930336, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-16285907, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-16341066, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-16467855, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-16686531, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-17150306, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-17160644, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-17193697, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-17241121, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-17567119, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-17714508, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-17764959, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-17826690, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-2025413, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-3667587, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-7665226, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-9187245, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-9610707, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-9622670, http://linkedlifedata.com/resource/pubmed/commentcorrection/18234225-9685395
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1089-8638
pubmed:author
pubmed:issnType
Electronic
pubmed:day
7
pubmed:volume
376
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1438-50
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.
pubmed:affiliation
Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. cyril@ncifcrf.gov
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Intramural